Olink

Olink®
Part of Thermo Fisher Scientific

The influence of elevated body mass index on protein expression in pediatric b-cell acute lymphoblastic leukemia

Pediatric Hematology and Oncology, 2026

Werk R., Chacón J., Turcotte L., Ryder J.

Disease areaApplication areaSample typeProducts
Oncology
Pathophysiology
Serum
Olink Target 96

Olink Target 96

Abstract

This study explored protein expression in B-cell acute lymphoblastic leukemia (B-ALL) patients with and without elevated weight or obesity and controls to understand global proteomic differences between newly diagnosed B-ALL patients and controls as well as the influences of elevated body mass index (BMI) on pretreatment inflammatory and immune-related protein expression in B-ALL patients. Protein expression was measured in serum samples of pediatric patients (aged 1-21 years) with newly diagnosed B-ALL (n = 39), and age and sex-matched controls (n = 41) using OLink panels. We examined normalized protein expression data clustered by patient information in ­unsupervised hierarchical clustering and principal component analysis. Of 239 assays, 128 assays differed significantly based on B-ALL diagnosis and 4 assays (APLP1, CDHR5, GHRL, SEZ6L) varied significantly as a function of BMI. In healthy individuals, oncology marker furin (p.adjust = 0.016) was more highly expressed in the high-BMI category; this trend was reversed for B-ALL individuals. Furin expression is often upregulated in malignancies and obesity; however this suggests its expression may follow unique patterns in pediatric B- ALL patients with elevated BMI.

Read publication ↗